Mouse models have been essential for establishing the role of the T cells in anti-tumor responses, but they have limited utility in translational studies for the testing of candidate therapeutics due to lack of cross-reactivity of many human antibodies to mouse receptors. Most of the human cell-based models for studying anti-tumor T cell responses, however, have significant biological or practical limitations that constrain their usefulness.
In this webinar, Dr. Michael Overstreet from AstraZeneca will discuss the development of a model system to study antigen-specific T cell-mediated cytotoxicity of HLA-matched human tumor cells based on memory anti-viral T cells. This presentation will show how optimizing this model using real-time instrumentation has led to new understanding of the interplay among the dynamic variables that impact the interactions between tumor cells and T cells.
Tune in to learn more about:
- Approaches to modeling and studying HLA-restricted anti-tumor T cell responses without access to primary tumor samples
- Variables that can dramatically impact these types of studies
- How using both impedance measurement and imaging has impacted our understanding of the dynamics of these assays